Skip to main content

Table 3 Kaplan-Meier progression-free survival (PFS) and overall survival (OS) estimates stratified by CTC level and patient and tumor characteristics in patients with newly diagnosed metastatic IBC

From: Circulating tumor cells in newly diagnosed inflammatory breast cancer

 

Progression-free survival

Overall survival

Variable

Hazard ratio

Lower 95% CI

Upper 95% CI

P value

Hazard ratio

Lower 95% CI

Upper 95% CI

P value

All patients

        

<1 CTC vs. ≥ 1 CTC

0.40

0.21

0.75

0.03

0.29

0.14

0.62

0.03

<5 CTC vs. ≥ 5 CTC

0.76

0.43

1.31

0.30

0.65

0.35

1.19

0.15

ER/PR positive for either

        

<1 CTC vs. ≥ 1 CTC

0.30

0.13

0.67

0.03

0.14

0.05

0.37

0.02

<5 CTC vs. ≥ 5 CTC

0.57

0.27

1.20

0.13

0.54

0.24

1.22

0.14

ER/PR negative for both

        

<1 CTC vs. ≥ 1 CTC

0.69

0.24

2.00

0.54

0.64

0.19

2.19

0.54

<5 CTC vs. ≥ 5 CTC

0.97

0.41

2.27

0.94

0.67

0.26

1.73

0.37

HER-2/neu positive

        

<1 CTC vs. ≥ 1 CTC

0.22

0.05

0.90

0.11

NA a

NA a

NA a

0.11

<5 CTC vs. ≥ 5 CTC

0.82

0.20

3.32

0.78

0.48

0.10

2.36

0.38

HER-2/neu negative

        

<1 CTC vs. ≥ 1 CTC

0.75

0.32

1.72

0.53

0.52

0.21

1.29

0.26

<5 CTC vs. ≥ 5 CTC

0.66

0.36

1.22

0.16

0.58

0.30

1.14

0.09

Triple negative

        

<1 CTC vs. ≥ 1 CTC

0.92

0.22

3.79

0.91

0.79

0.20

3.04

0.74

<5 CTC vs. ≥ 5 CTC

0.34

0.10

1.14

0.01

0.35

0.10

1.28

0.02

High Grade

        

<1 CTC vs. ≥ 1 CTC

0.38

0.19

0.77

0.03

0.23

0.10

0.54

0.03

<5 CTC vs. ≥ 5 CTC

0.61

0.31

1.18

0.11

0.54

0.26

1.12

0.08

Low/intermediate grade

        

<1 CTC vs. ≥ 1 CTC

0.75

0.12

4.54

0.77

1.05

0.13

8.45

0.96

<5 CTC vs. ≥ 5 CTC

1.30

0.44

3.87

0.61

0.87

0.28

2.71

0.81

Visceral metastases

        

<1 CTC vs. ≥ 1 CTC

0.13

0.05

0.32

0.01

0.00

0.00

0.00

0.03

<5 CTC vs. ≥ 5 CTC

0.66

0.30

1.45

0.28

0.49

0.21

1.16

0.07

Non-visceral metastases

        

<1 CTC vs. ≥ 1 CTC

0.66

0.28

1.56

0.39

0.62

0.22

1.77

0.44

<5 CTC vs. ≥ 5 CTC

0.87

0.40

1.88

0.71

0.78

0.33

1.83

0.55

Bone metastasis

        

<1 CTC vs. ≥ 1 CTC

0.29

0.13

0.66

0.03

0.18

0.06

0.50

0.06

<5 CTC vs. ≥ 5 CTC

0.67

0.31

1.43

0.28

0.51

0.22

1.20

0.12

No-bone metastasis

        

<1 CTC vs. ≥ 1 CTC

0.56

0.21

1.51

0.33

0.47

0.16

1.41

0.29

<5 CTC vs. ≥ 5 CTC

0.78

0.34

1.79

0.55

0.78

0.32

1.87

0.56

  1. ER, estrogen receptor; NR, not reached; PR, progesterone receptor; NA, not applicable.
  2. aNo events in patients with fewer than one CTCs.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us